Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jonathan A Fletcher

Showing results (71-80 of 205) with videos related to

Pageof 21
Sort By:
Cancers|September 30, 2020
AXL Inactivation Inhibits Mesothelioma Growth and Migration via Regulation of p53 ExpressionWei Song, Hao Wang, Minmin Lu, et al.
The American Journal of Pathology|December 26, 2003
KIT mutations are common in testicular seminomasKathleen Kemmer, Christopher L Corless, Jonathan A Fletcher, et al.
Cancer Research|August 27, 2009
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumorsThomas Mühlenberg, Yixiang Zhang, Andrew J Wagner, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|October 1, 2004
Gastrointestinal stromal tumours: etiology, pathology and clinical managementMartin E Blackstein, Pierre Dubé, Jonathan A Fletcher, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 17, 2020
Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST)Mazen A Atiq, Jessica L Davis, Jason L Hornick, et al.
British Journal of Cancer|October 14, 2016
Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53Wen-Bin Ou, Minmin Lu, Grant Eilers, et al.
Journal of Neurosurgery|August 20, 2003
Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. Report of two casesFederico Roncaroli, Vania Nosé, Bernd W Scheithauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225Grant A McArthur, George D Demetri, Allan van Oosterom, et al.
The Oncologist|June 14, 2015
Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert DiscussionRobert G Maki, Jean-Yves Blay, George D Demetri, et al.
American Journal of Clinical Pathology|August 10, 2004
HER-2/neu testing in breast cancerJeffrey S Ross, Jonathan A Fletcher, Kenneth J Bloom, et al.
Pageof 21

Showing results (71-80 of 205) with videos related to

Sort By:
Pageof 21
Cancers|September 30, 2020
AXL Inactivation Inhibits Mesothelioma Growth and Migration via Regulation of p53 ExpressionWei Song, Hao Wang, Minmin Lu, et al.
The American Journal of Pathology|December 26, 2003
KIT mutations are common in testicular seminomasKathleen Kemmer, Christopher L Corless, Jonathan A Fletcher, et al.
Cancer Research|August 27, 2009
Inhibitors of deacetylases suppress oncogenic KIT signaling, acetylate HSP90, and induce apoptosis in gastrointestinal stromal tumorsThomas Mühlenberg, Yixiang Zhang, Andrew J Wagner, et al.
Canadian Journal of Gastroenterology = Journal Canadien De Gastroenterologie|October 1, 2004
Gastrointestinal stromal tumours: etiology, pathology and clinical managementMartin E Blackstein, Pierre Dubé, Jonathan A Fletcher, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|July 17, 2020
Mesenchymal tumors of the gastrointestinal tract with NTRK rearrangements: a clinicopathological, immunophenotypic, and molecular study of eight cases, emphasizing their distinction from gastrointestinal stromal tumor (GIST)Mazen A Atiq, Jessica L Davis, Jason L Hornick, et al.
British Journal of Cancer|October 14, 2016
Co-targeting of FAK and MDM2 triggers additive anti-proliferative effects in mesothelioma via a coordinated reactivation of p53Wen-Bin Ou, Minmin Lu, Grant Eilers, et al.
Journal of Neurosurgery|August 20, 2003
Gonadotropic pituitary carcinoma: HER-2/neu expression and gene amplification. Report of two casesFederico Roncaroli, Vania Nosé, Bernd W Scheithauer, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 1, 2005
Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: Imatinib Target Exploration Consortium Study B2225Grant A McArthur, George D Demetri, Allan van Oosterom, et al.
The Oncologist|June 14, 2015
Key Issues in the Clinical Management of Gastrointestinal Stromal Tumors: An Expert DiscussionRobert G Maki, Jean-Yves Blay, George D Demetri, et al.
American Journal of Clinical Pathology|August 10, 2004
HER-2/neu testing in breast cancerJeffrey S Ross, Jonathan A Fletcher, Kenneth J Bloom, et al.
Pageof 21